From GlobeNewswire: 2025-05-16 13:52:00

Alvotech, a global biotech company, has successfully completed an offering of Swedish Depository Receipts (SDRs) in connection with its listing on Nasdaq Stockholm. The offering was multiple times oversubscribed, resulting in more than 3,000 new shareholders for Alvotech. The final offering price was set at SEK 87.51 per SDR, with gross proceeds amounting to approximately SEK 39 million. Trading on Nasdaq Stockholm under the ticker symbol “ALVO SDB” will begin on May 19, 2025. Alvotech aims to expand its R&D capabilities and has recently acquired Xbrane Biopharma AB’s R&D operations in Sweden to support its growth trajectory and innovation efforts.

Alvotech’s listing on Nasdaq Stockholm is expected to enhance its recognition in the Nordic and European markets, attracting a broader base of institutional and retail investors. The company plans to enter into an agreement with a market maker to promote liquidity in the SDRs. Shareholders who owned the company prior to the offering will have a free conversion period to convert their shares into SDRs. Alvotech’s commercial partnerships with various pharmaceutical companies aim to provide global reach for its biosimilar products, catering to patients worldwide.

DNB Carnegie Investment Bank AB (publ) and DNB Markets are acting as financial advisors for the offering, with legal advisors from Cirio Advokatbyrå AB, Westerberg & Partners, and other firms. Alvotech’s forward-looking statements highlight the company’s growth prospects, pipeline development, and regulatory interactions. Investors are advised to make decisions based on publicly available information and must consider the risks associated with investing in the company. For more information, visit Alvotech’s investor portal and website or follow them on social media.



Read more at GlobeNewswire: Alvotech Announces the Outcome of the Offering in